KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) Non Operating Income (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Non Operating Income for 9 consecutive years, with $362000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 104.42% to $362000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, up 176.23% year-over-year, with the annual reading at $5.9 million for FY2025, 173.74% up from the prior year.
  • Non Operating Income hit $362000.0 in Q4 2025 for Bionano Genomics, up from $49000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.4 million in Q1 2025 to a low of -$16.9 million in Q4 2023.
  • Historically, Non Operating Income has averaged -$1.1 million across 5 years, with a median of -$40000.0 in 2021.
  • Biggest five-year swings in Non Operating Income: surged 6688.89% in 2021 and later plummeted 42030.0% in 2023.
  • Year by year, Non Operating Income stood at -$955000.0 in 2021, then skyrocketed by 95.81% to -$40000.0 in 2022, then tumbled by 42030.0% to -$16.9 million in 2023, then soared by 51.44% to -$8.2 million in 2024, then surged by 104.42% to $362000.0 in 2025.
  • Business Quant data shows Non Operating Income for BNGO at $362000.0 in Q4 2025, $49000.0 in Q3 2025, and $953000.0 in Q2 2025.